Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia - Trial NCT06402370
Access comprehensive clinical trial information for NCT06402370 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Ghent and is currently Recruiting. The study focuses on MCI. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Ghent
Timeline & Enrollment
N/A
May 08, 2024
May 01, 2026
Primary Outcome
N-status,A-status
Summary
The National Institute on Aging together with the Alzheimer's Association (NIA-AA) recently
 proposed the ATN classification which is based upon the pathological processes present in
 Alzheimer's disease (amyloid, tau and neurodegeneration). The amyloid and tau status can be
 defined using cerebrospinal fluid analysis but also non-invasively using an amyloid or tau
 PET scan. The N status can be defined using an [18F]-FDG PET scan which is in Belgium part of
 standard of care. Recently, it has been demonstrated, using different amyloid PET tracers,
 that early-frame amyloid scans can be a surrogate for [18F]-FDG PET scan.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06402370
Non-Device Trial